In a reverse-translational study followed by a clinical trial, the targeting of antigen-presenting mast cells was identified as a therapeutic approach to overcome anti-PD-1 resistance in patients with metastatic triple-negative breast cancer who experienced clinical benefit when treated with the mast cell stabilizer cromolyn.
- Song-Yang Wu
- Xi Jin
- Yi-Zhou Jiang
